Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07246889 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE)

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Mar 1, 2027 to Dec 18, 2026
    • Study completion date: Sep 1, 2027 to Oct 31, 2027
    v3
  2. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 540 to confirmed 577
    • Study sites: 39 to 28
    • Eligibility criteria expanded, about 8 words
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a randomized, double-blind, multicenter phase 3 clinical trial to evaluate the efficacy and safety of AHB-137 injection in participants with HBeAg-negative CHB treated with NAs.
Trial Details
NCT Number NCT07246889
Lead Sponsor Ausper Biopharma Co., Ltd.
Conditions
(from sponsor)		 Chronic Hepatitis B
Related terms Hepatitis B, Chronic
Enrollment 577 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov